Collectively, these data highlight the importance of BCL-xL as a/the maintenance molecular determinant of TIS cancer cells and the potential to circumvent the side effects associated with BCL-xL-targeted therapies in translating one-two punch senogenic-senolytic strategies from experimental models to the clinical arena. Here, BCL2L1 is linked to cancer.